Chinese Hamster Ovary (CHO) cells remain the gold standard for therapeutic antibody and biologics production, thanks to their scalability, robust growth, and human-like glycosylation profiles. Among these, CHO-K1 cell lines have proven to enable consistent, high-yield manufacturing of monoclonal antibodies and other biologics.
To support biopharma companies worldwide, Biointron offers a commercial license for CHOK1BN - a perpetual, irrevocable, and compliant licensing solution that empowers developers to streamline their antibody discovery and manufacturing pipelines.
Biointron’s CHOK1BN cell line is sourced from ECACC and specifically adapted for suspension culture in chemically defined (CD) medium. It is fully traceable back to the original CHO cell line, ensuring confidence in regulatory compliance and scientific integrity.
Designed for flexibility and efficiency, CHOK1BN provides a reliable foundation for antibody development projects across diverse therapeutic modalities.
Chinese Hamster Ovary (CHO) cells have been the workhorse of biologics manufacturing for more than 60 years. First isolated and immortalized by Theodore Puck in 1956, CHO cells have since been refined into multiple subclones optimized for recombinant protein expression and therapeutic antibody production.
Over decades, scientists have introduced targeted mutations, adapted cells to suspension culture, and leveraged metabolic selection systems to improve productivity. For example:
CHO DXB11 (dhfr+/–) and CHO DG44 (dhfr–/–) use the dihydrofolate reductase (DHFR)-methotrexate system, which not only facilitates clone selection but also serves as a gene amplification tool for higher yields.
CHO-GS–/– (CHO-K1SV) applies the glutamine synthetase (GS)-methionine sulfoximine system for more efficient clone selection.
CHO-S and its derivatives have been adapted to serum-free suspension culture, enabling high cell density and volumetric productivity.
Despite originating from the same ancestor, CHO lineages exhibit substantial genetic heterogeneity due to mutagenesis and clonal selection. This diversity explains why CHO-K1, CHO-S, DG44, and DXB11 each display unique growth patterns and expression strengths. Comparative studies, for instance, have shown that CHO-K1 cells favor higher cell-specific productivity (7–16 pg/cell/day), while CHO-S cells excel in biomass production but yield lower antibody titers (2–6 pg/cell/day).
Continuous research has enhanced CHO productivity and stability through strategies such as:
Overexpressing beneficial genes involved in proliferation, stress resistance, and secretion.
Silencing disadvantageous genes (e.g., pro-apoptotic or metabolic bottlenecks).
Exploiting microRNAs (miRNAs) to reprogram cellular pathways for higher yields.
Using CRISPR/Cas9 and other genome-editing tools for targeted integration at “hot spots” to achieve stable, predictable expression.
These innovations have enabled engineered CHO lines to reach record productivities of 3–7 g/L in lab settings. However, industrial bottlenecks such as downstream processing and production instability remain challenges. Research continues to focus on enhancing clonal stability, targeted integration, and long-term culture performance.
Despite their genomic plasticity and inherent instability, CHO cells remain unmatched in adaptability, scalability, and regulatory acceptance. Their ability to be engineered and optimized has ensured their continued dominance in biologics production, and they are unlikely to be replaced in the near future.
Biointron’s CHOK1BN cell line builds on this history, offering a suspension-adapted, high-stability platform that combines decades of CHO innovation with a ready-to-license commercial solution for antibody manufacturing.
While CHO cells have long been the backbone of biologics manufacturing, they are not without challenges. One of the most well-recognized issues is their inherent genetic instability, which can lead to variability in antibody yields and product quality.
Recent multi-omics studies have shown that during adaptation to serum-free suspension culture, CHO cells undergo both random genetic drift and heritable changes driven by culture conditions, selection criteria, and gene editing. These adaptations are often linked to:
Chromosomal rearrangements and losses (notably in chromosomes 2, 9, 10, and X)
Thousands of small insertions, deletions, and single-nucleotide polymorphisms
Copy number variations that accumulate with extended culture and genetic manipulation
This genomic “plasticity” is a double-edged sword: while it allows CHO cells to adapt to industrial demands, it also makes them prone to lot-to-lot variability and production inconsistency. Even with site-specific integration or isogenic cloning, clonal populations can still exhibit phenotypic divergence over time, complicating long-term stability.
For therapeutic antibody developers, inconsistency in protein expression or product quality is not just a technical inconvenience — it poses risks to regulatory approval, manufacturing reliability, and commercial scalability. Addressing this challenge requires access to well-characterized, validated CHO platforms that have already undergone adaptation for stable, high-yield performance.
This is where Biointron’s CHOK1BN commercial license provides a decisive advantage. By licensing a fully traceable, suspension-adapted, and stability-tested host cell line, companies can bypass years of risky adaptation and ensure consistent performance across production campaigns.
Suspension-adapted in basic CD medium for broad compatibility
Flexibility to choose the optimal medium and formulation for your antibody production workflow
Antibody yields exceeding 10 g/L
Proven genetic and phenotypic stability to ensure consistent performance across production runs
Supports monoclonal antibodies, bispecifics, Fc-fusions, and proteins
Versatility enables developers to pursue a wide range of biologics without limitations
Unlike time-limited or restrictive models, Biointron’s CHOK1BN license is perpetual and irrevocable, requiring only a one-time sublicense fee. This offers companies both freedom-to-operate and long-term security in their development programs.
Streamlined Licensing Process
Licensed directly from ECACC (Contract No. BYC-SHSWZP211027)
Per-project sublicense fee model — contact Biointron for tailored details
Immediate access to a validated, regulatory-ready host system
When licensing CHOK1BN from Biointron, you receive not just the cell line, but also a complete package of supporting documentation and protocols to accelerate development.
Deliverables include:
Host system: CHOK1BN cell line
Documentation:
ECACC license order form & original invoice
Certificate of Analysis (COA)
Customs clearance report
Suspension-adapted report
Cell banking detection report (sterility, mycoplasma, viral contaminants, etc.)
COAs for FBS and Trypsin
Protocols:
Cell culture protocol
CHO stable cell line development protocol (covering transfection, pool screening, and clone screening)
This complete package ensures that your team can move forward seamlessly, with full traceability and compliance documentation in place.
Biointron has extensive expertise in antibody discovery and expression, enabling us to support biopharma partners globally. By offering the CHOK1BN commercial license, we provide:
A proven, regulatory-friendly host cell line
Freedom to operate without recurring fees
Comprehensive technical and compliance documentation
Confidence in long-term scalability for clinical and commercial programs
For companies developing therapeutic antibodies and next-generation biologics, Biointron’s CHOK1BN commercial license provides a perpetual, compliant, and highly productive solution. Instead of investing years into de novo host cell line development, you can accelerate your pipeline with a validated, scalable, and regulatory-accepted CHO platform. Looking for a trusted host cell line for antibody development?
Contact Biointron today to learn more about licensing CHOK1BN for your commercial projects.
References:
Tihanyi, B., & Nyitray, L. (2020). Recent advances in CHO cell line development for recombinant protein production. Drug Discovery Today: Technologies, 38, 25-34. https://doi.org/10.1016/j.ddtec.2021.02.003
Huhn, S., Chang, M., Kumar, A., Liu, R., Jiang, B., Betenbaugh, M., Lin, H., Nyberg, G., & Du, Z. (2022). Chromosomal instability drives convergent and divergent evolution toward advantageous inherited traits in mammalian CHO bioproduction lineages. IScience, 25(4), 104074. https://doi.org/10.1016/j.isci.2022.104074
As of the end of 2025, 21 ADCs have been approved globally, with four new approv……
Antibody engineering has progressed beyond classical depletion and neutralizatio……
The 2025 Antibody Engineering & Therapeutics US (AET US) conference was held in ……
The 2025 mAbTalk Symposium by The Chinese Antibody Society was held in San Deigo……
You can also contact us on the Scientist and Science Exchange marketplaces.
